Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver, Roy P. M. Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B. Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P. ZweemerLeonardus F. Massuger, Michael R. Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse, Frederic Amant

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalClinical Cancer Research
Volume23
Issue number5
Pages (from-to)1274-1285
Number of pages12
ISSN1078-0432
DOIs
Publication statusPublished - 1 Mar 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • ENDOMETRIAL STROMAL SARCOMA
  • SOFT-TISSUE SARCOMA
  • GROWTH-FACTOR RECEPTOR
  • AKT-MTOR PATHWAY
  • MAMMALIAN TARGET
  • BREAST-CANCER
  • CYCLIN D1
  • EXPRESSION
  • TUMORS
  • TRIAL
  • 3122 Cancers

Cite this

Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., ter Haar, N., Colas, E., Garcia-Jimenez, A., Van de Vijver, K., Kruitwagen, R. P. M., Brinkhuis, M., Zikan, M., Dundr, P., Huvila, J., Carpen, O., Haybaeck, J., Moinfar, F., Salvesen, H. B., Stukan, M., Mestdagh, C., ... Amant, F. (2017). Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. Clinical Cancer Research, 23(5), 1274-1285. https://doi.org/10.1158/1078-0432.CCR-16-2149